SG/CALL/NOVO-NORDISK B/1100/0.1/19.06.26 | Market Closed - Boerse Frankfurt Warrants 01:14:19 01/06/2024 am IST | ||
| 2.12 EUR | +1.92% |
|
| 1 month | -6.22% | ||
| 3 months | +20.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 2.11 | +1.44% |
| 30/24/30 | 2.08 | -0.95% |
| 29/24/29 | 2.1 | -2.78% |
| 28/24/28 | 2.16 | -3.57% |
| 27/24/27 | 2.24 | -3.45% |
Real-time Boerse Frankfurt Warrants
Last update May 01, 2024 at 01:14 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU9CV5 |
| ISIN | DE000SU9CV56 |
| Date issued | 14/02/2024 |
| Strike | 1,100 kr |
| Maturity | 19/06/2026 (747 Days) |
| Parity | 10 : 1 |
| Emission price | 1.75 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.57 € |
|---|---|
| Lowest since issue | 1.68 € |
| Spread | 0.03 € |
| Spread % | 1.36% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Warrants
- Warrant
